CL2024002529A1 - Tratamiento del cáncer dirigido a dll3 - Google Patents

Tratamiento del cáncer dirigido a dll3

Info

Publication number
CL2024002529A1
CL2024002529A1 CL2024002529A CL2024002529A CL2024002529A1 CL 2024002529 A1 CL2024002529 A1 CL 2024002529A1 CL 2024002529 A CL2024002529 A CL 2024002529A CL 2024002529 A CL2024002529 A CL 2024002529A CL 2024002529 A1 CL2024002529 A1 CL 2024002529A1
Authority
CL
Chile
Prior art keywords
dll3
cancer treatment
targeted cancer
agent
treatment
Prior art date
Application number
CL2024002529A
Other languages
English (en)
Spanish (es)
Inventor
MINOCHA Mukul
Hashemi Sadraei Nooshin
Goldrick Amanda
Chen Xi
KISTLER Mira
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2024002529A1 publication Critical patent/CL2024002529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2024002529A 2022-02-23 2024-08-23 Tratamiento del cáncer dirigido a dll3 CL2024002529A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263313119P 2022-02-23 2022-02-23
US202263429311P 2022-12-01 2022-12-01

Publications (1)

Publication Number Publication Date
CL2024002529A1 true CL2024002529A1 (es) 2025-01-24

Family

ID=85724660

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002529A CL2024002529A1 (es) 2022-02-23 2024-08-23 Tratamiento del cáncer dirigido a dll3

Country Status (12)

Country Link
US (1) US20250154247A1 (enExample)
EP (1) EP4482586A1 (enExample)
JP (1) JP2025508786A (enExample)
KR (1) KR20240153575A (enExample)
AU (1) AU2023224210A1 (enExample)
CA (1) CA3252459A1 (enExample)
CL (1) CL2024002529A1 (enExample)
IL (1) IL314195A (enExample)
JO (1) JOP20240188A1 (enExample)
MX (1) MX2024010330A (enExample)
TW (1) TW202342096A (enExample)
WO (1) WO2023164474A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080688A1 (en) * 2023-10-12 2025-04-17 Amgen Inc. Compositions of bispecific antibody constructs to human dll3 and human cd3
WO2025193578A1 (en) * 2024-03-11 2025-09-18 Amgen Inc. Method of treating brain metastases in subjects with a dll3-positive cancer
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026075950A1 (en) * 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
KR20220162690A (ko) 2020-01-31 2022-12-08 젠선 바이오파마, 인코포레이티드 이중특이성 t 세포 관여항체
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
KR20240006585A (ko) * 2021-05-10 2024-01-15 암젠 인크 Dll3 및 pd-1을 표적으로 하는 병용 요법을 위한 투여 요법

Also Published As

Publication number Publication date
CA3252459A1 (en) 2023-08-31
AU2023224210A1 (en) 2024-07-18
EP4482586A1 (en) 2025-01-01
WO2023164474A1 (en) 2023-08-31
KR20240153575A (ko) 2024-10-23
IL314195A (en) 2024-09-01
TW202342096A (zh) 2023-11-01
JP2025508786A (ja) 2025-04-10
MX2024010330A (es) 2024-08-30
US20250154247A1 (en) 2025-05-15
JOP20240188A1 (ar) 2024-08-19

Similar Documents

Publication Publication Date Title
MX2024010330A (es) Tratamiento del cancer dirigido a dll3.
CL2023003357A1 (es) Régimen de dosis para terapia combinada dirigida a dll3 y pd-1
UY38948A (es) Régimen de dosificación para agentes anti-dll3
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
AR104771A1 (es) Inhalador de polvo seco
UY40260A (es) Unión de heteromultímeros dll3 y cd3
CO2023009635A2 (es) Conjugado de anticuerpo anti-dll3-fármaco
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4
CL2025002930A1 (es) Programa de dosificación de un inhibidor de her.2
MX2024004514A (es) Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
CL2023002914A1 (es) Dosificación y administración de l-asparaginasa recombinante
Subramanium et al. Nimotuzumab with induction chemotherapy and chemo-radiation in patients with advanced head and neck cancer
Nayak et al. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post-hoc analysis of the AVERT trial
AR122043A1 (es) Dosificación y administración del anticuerpo anti-ctla-4 activable
PL433511A1 (pl) Zastosowanie lidokainy w leczeniu ostrego zapalenia trzustki
MX2024012073A (es) Regimen de dosis y administracion para el tratamiento o prevencion del sindrome de guillan-barre mediante el uso del anticuerpo anti cumulo 5 (anti-c5) crovalimab
MX2024011932A (es) Combinaciones farmaceuticas y metodos de uso del compuesto de amino-pirrolopirimidinona
Aroda et al. Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine in patients with T2DM: the LixiLan-L trial (NCT02058160): 111E.